10:45 AM EDT, 08/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target by $71 to $750, 20x our FY 26 EPS estimate (up $0.07 to $37.41; FY 27 estimate down $0.03 to $41.91), a premium to peers to reflect stronger margins and attractive EPS/dividend growth, in our view, and above MCK's three-year forward average (16.9x) due to sales momentum from strong pharma volumes, including GLP-1 drugs, and healthy FCF supporting capital returns. With the recent announcement of its Norway sale, MCK is poised to complete its multiyear exit from European operations. Combined with a potential near-term spin-off of the Medical-Surgical business, we expect the European exit will help company to focus more intensely on U.S. and Canadian pharma distribution operations and investments in oncology and biopharma opportunities. We continue to view pharma distributors as less exposed to regulatory and tariff risks in this environment.